Skip to content ↓

The social entrepreneurs of SA+P

A sampling of non-profit organizations founded by alumni
Founded in 1999 by Elisabeth Stock (’90, MCP’95, SM’95) and Dan Dolgin, a lawyer and private investor, CFY is a national education nonprofit that helps students in low-income communities, together with their teachers and families, harness the power of digital learning to improve educational outcomes.
Caption:
Founded in 1999 by Elisabeth Stock (’90, MCP’95, SM’95) and Dan Dolgin, a lawyer and private investor, CFY is a national education nonprofit that helps students in low-income communities, together with their teachers and families, harness the power of digital learning to improve educational outcomes.

Much is made of the impact of companies founded by MIT alumni, and of the entrepreneurial culture fostered at the Institute. But less widely noted is the impact of non-profit organizations led and founded by our alumni, carrying out MIT’s parallel culture of social entrepreneurship.

Over the years, alumni of the School of Architecture + Planning have been prominent among the Institute’s social entrepreneurs with scores, perhaps even hundreds of graduates holding leadership positions in well-established non-profits. And in recent years a growing number of those non-profits have actually been founded by our alumni.

The capsule descriptions included here provide a brief overview of some of those efforts.

Read more

Related Links

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story